injectable bpc 157 and tb 500 BPC-157/KPV/TB500 BPC-157 & TB-500 Blend For

Sermorelin's FDA Journey: Approved, Discontinued, and Compounded Sermorelin acetate (Geref) was FDA-approved in 1997 for pediatric GHD 1 and in 1990 for diagnostic use.26 The manufacturer discontinued Geref in 2008 due to "manufacturing difficulties," not safety or efficacy concerns.12 In 2013, the FDA confirmed it wasn't withdrawn for safety/effectiveness, allowing for potential generic approvals.12 Currently, Sermorelin is primarily available as a compounded medication 3, which is permitted but not individually FDA-approved like mass-produced drugs.22 5.2

Its unique profile makes it an attractive compound for exploring the therapy of metabolic disease and muscle aging, as well as evaluating the intricate links between metabolism, epigenetics, and tissue function 1-4

It is a synthetic analog of human growth hormone (HGH), originating from the modification of the growth hormones last 16 amino acids at positions 176 to 191

In the United States, the FDA regulates hCG as a prescription drug, so it is sold only for laboratory and research purposes